Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Wu Capital

BioCentury | May 13, 2022
Emerging Company Profile

Nuvig: bringing immune homeostasis to inflammatory disease with a $47M A round

Backed by Novo Holdings and Platanus, Nuvig is designing proteins to selectively suppress active immune pathways
BioCentury | Jan 6, 2022
Finance

Jan. 5 Quick Takes: Eventide leads mega-round by Korro

Plus Saliogen raises $115M series B and updates from 
BioCentury | Aug 18, 2021
Emerging Company Profile

Ranok: a chaperone-based approach to targeted degradation

Emerging Company Profile: Ranok has raised $40M to test whether alternative to PROTACs could have safety, dosing advantages
BioCentury | Nov 14, 2020
Emerging Company Profile

Ex-Mavupharma execs reunite at Inipharm to build liver disease pipeline

Emerging Company Profile: Inipharm will use its $35M series A to advance lead liver program through Phase I
BioCentury | Oct 20, 2020
Deals

Oct. 19 Quick Takes: Genesis, Genentech in AI drug discovery deal; plus Endo-BioSpecifics, Gemini, Catalyst-Jacobus, ONK, Venclexta  

Genesis and Genentech collaborate to identify drug candidates using AIStanford spinout and AI platform company Genesis Therapeutics Inc. entered into a collaboration agreement with the
BioCentury | Sep 10, 2020
Finance

Korro Bio’s $91.5M series A brings in new investors, launches hunt for CEO

Korro Bio’s $91.5 million series A round opens the door to new leadership for the Atlas-built RNA editing company, which has been led by Executive Chairman Nessan Bermingham since its
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

The next act for neoantigens includes cell therapies and a broader range of targets
Items per page:
1 - 10 of 13
Username